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DNA testing for high risk of prostate cancer
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Association studies of candidate genes in DNA repair
and cell cycle control pathways identified mutations
associated with a susceptibility to prostate cancer in
BRCA1, BRCA2, CHEK2, NBS1 and BRIP1 genes. Muta-
tions in these genes confer 1.5- to 6-fold increase in the
risk of prostate cancer. In general, the risks associated
with these mutations are higher in carriers who report
family history of prostate cancer (the risk increased 3-
to 15-fold).
Our studies confirm that rare mutations in DNA
damage repair genes are associated with a predisposition
to prostate cancer. Specific mutations in NBS1, BRCA1
and CHEK2 genes are associated with 1.6- to 4.6-fold
increased risk for prostate cancer in the Polish popula-
tion. The risk is higher, increased approximately 5 - 15
fold, in carriers who report prostate cancer in at least
one first and/or second degree relative.
In the past three years, new DNA markers of low
penetration for prostate cancer were identified by
GWAS studies. Of these markers, the strongest associa-
tion with disease risk was seen for markers of chromo-
some 8q24. We analyzed how markers of this region
influence prostate cancer risk in a in a series of cases
and controls from Poland. Single markers of 8q24 were
associated with a low penetrance for prostate cancer -
approximately 1.5- fold increased risk (ORs ranged from
1.4 to 1.6). Carriers of two different markers had the
risk increased on average by 2,5-fold. Carriers of risk
alleles of three markers had on average 6-fold increased
risk. Carriers of five markers of 8q24 had an odd ratio
of 10.7 for prostate cancer (95% CI 3.3 - 36).
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